Table 1

Bivariate relationships between substance use disorders (SUD) and interferon (IFN) completion and response rates among veterans with available hepatitis C (HCV) genotypes

SUD- Group
 SUD+ Group







N
 %
 N
 %
 OR
 95% CI
 p
Known vs. Unknown Genotype






     Not available
 42
 12.0%
 52
 11.2%
 1.08
 0.70–1.67
 0.718
     Available
 308
 88.0%
 413
 88.8%










Genotypes 2 & 3






Completed ≥ 22 Weeks of IFN






     No
 29
 26.9%
 56
 32.0%
 0.78
 0.46 – 1.33
 0.359
     Yes
 79
 73.1%
 119
 68.0%


End of Treatment Response (ETR)






     Not available
 8
 7.4%
 9
 5.1%
 1.38
 0.51 – 3.74
 0.528
     Available
 71
 65.7%
 110
 62.9%


          No Response
 14
 13.0%
 15
 8.6%
 1.56
 0.70 – 3.46
 0.276
          Response
 57
 52.8%
 95
 54.3%


Sustained Viral Response (SVR)






     Not available
 4
 3.7%
 8
 4.6%
 0.79
 0.23 – 2.73
 0.705
     Available
 61
 56.5%
 96
 54.9%


          No Response
 15
 13.9%
 24
 13.7%
 0.98
 0.47 – 2.06
 0.954
          Response
 46
 42.6%
 72
 41.1%










Genotypes 1 & 4






Completed ≥ 46 Weeks of IFN






     No
 121
 60.5%
 143
 60.1%
 1.02
 0.69 – 1.49
 0.929
     Yes
 79
 39.5%
 95
 39.9%


End of Treatment Response (ETR)






     Not available
 9
 8.3%
 19
 10.9%
 0.51
 0.22 – 1.21
 0.124
     Available
 70
 64.8%
 76
 43.4%


          No Response
 21
 19.4%
 17
 9.7%
 1.49
 0.71 – 3.13
 0.294
          Response
 49
 45.4%
 59
 33.7%


Sustained Viral Response (SVR)






     Not available
 3
 2.8%
 4
 2.3%
 1.01
 0.22 – 4.69
 0.991
     Available
 55
 50.9%
 74
 42.3%


          No Response
 23
 21.3%
 21
 12.0%
 1.81
 0.87 – 3.79
 0.111
          Response
 32
 29.6%
 53
 30.3%


CI = Confidence interval, ETR = End of treatment response, IFN = Interferon, OR = Odds ratio, SUD = Substance use disorder, SVR = Sustained viral response. ORs reflect the SUD+ Group compared with the SUD- Group. The SUD+ Group includes veterans with a history of substance use disorder. The SUD- Group includes veterans with no history of substance use disorder. Completion rates are based on all patients with available genotypes. Response rates are based on all patients with known HCV genotypes who initiated IFN therapy. Patients were considered non-responders if they failed to clear the virus or if they were lost to follow-up (e.g., unavailable ETR or SVR).

Huckans et al. Substance Abuse Treatment, Prevention, and Policy 2007 2:4   doi:10.1186/1747-597X-2-4

Open Data